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Abstract
Background: Transfusion practices in hospitalised patients are being re-evaluated, in part due to studies
indicating adverse effects in patients receiving large quantities of stored blood. Concomitant with this re-
examination have been reports showing variability in the use of specific blood components. This
investigation was designed to assess hospital variation in blood use and outcomes in cardiac surgery
patients.
Methods: We evaluated outcomes in 24,789 Medicare beneficiaries in the state of Michigan, USA who
received coronary artery bypass graft surgery from 2003 to 2006. Using a cohort design, patients were
followed from hospital admission to assess transfusions, in-hospital infection and mortality, as well as
hospital readmission and mortality 30 days after discharge. Multilevel mixed-effects logistic regression was
used to calculate the intrahospital correlation coefficient (for 40 hospitals) and compare outcomes by
transfusion status.
Results: Overall, 30% (95 CI, 20% to 42%) of the variance in transfusion practices was attributable to
hospital site. Allogeneic blood use by hospital ranged from 72.5% to 100% in women and 49.7% to 100%
in men. Allogeneic, but not autologous, blood transfusion increased the odds of in-hospital infection 2.0-
fold (95% CI 1.6 to 2.5), in-hospital mortality 4.7-fold (95% CI 2.4 to 9.2), 30-day readmission 1.4-fold (95%
CI 1.2 to 1.6), and 30-day mortality 2.9-fold (95% CI 1.4 to 6.0) in elective surgeries. Allogeneic transfusion
was associated with infections of the genitourinary system, respiratory tract, bloodstream, digestive tract
and skin, as well as infection with Clostridium difficile. For each 1% increase in hospital transfusion rates,
there was a 0.13% increase in predicted infection rates.
Conclusion: Allogeneic blood transfusion was associated with an increased risk of infection at multiple
sites, suggesting a system-wide immune response. Hospital variation in transfusion practices after coronary
artery bypass grafting was considerable, indicating that quality efforts may be able to influence practice and
improve outcomes.
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The practice of transfusion is in transition. Over the past
several decades a body of evidence has accumulated that
indicates various adverse effects in patients who receive
transfusions, particularly with exposure to allogeneic
blood (that is, blood received from a genetically dissimi-
lar individual) [1-5]. Effects include, but are not limited
to, postoperative pneumonia, sepsis, and mortality [1-5].
The most notable study to date, a randomised controlled
trial of liberal versus conservative red blood cell use [6],
demonstrated that, for patients who were less acutely ill,
mortality was lower in the group receiving fewer transfu-
sions and, for high risk patients, mortality was similar in
lower and higher transfusion groups. Recent studies have
implicated prolonged storage of blood products as an
important factor [7], although investigations of patients'
responses to specific stored blood components are ongo-
ing.
Variation in the use of blood components is substantial.
Data from patients who received coronary artery bypass
graft (CABG) surgery at 32 hospitals in the US (1996 to
2001) showed the maximum variation possible [8]. Dur-
ing the postoperative period, the use of red blood cells,
fresh-frozen plasma and platelets ranged from 0% (no
patients transfused) to 100% (all patients transfused) in
different hospitals. During the intraoperative period,
usage ranged from 0% to approximately 70% for red
blood cells and 0% to 50% for fresh-frozen plasma and
platelets.
Anticipating that practices may have changed within the
last 5 years, we designed a cohort study to evaluate the var-
iation of transfusion use in hospitals using more recent
data and to assess in-hospital infection, 30-day readmis-
sion, and 30-day mortality in patients by transfusion sta-
tus.
Methods
Participants
Subjects were all fee-for-service Medicare beneficiaries (n
= 24,789) who received CABG surgery (International
Classification of Diseases, Clinical Modification, ninth
edition (ICD-9) procedure codes 36.1×) from 2003 to the
end of 2006. Only patients 65 years of age or older, who
were Michigan residents or received their surgery in a
Michigan hospital, were included. In this retrospective
cohort study, patients were followed from hospital admis-
sion to 30 days after hospital discharge. Inpatient stand-
ard analytical files and denominator files were obtained
from the Centers for Medicare and Medicaid Services
(CMS), and contained information regarding hospitalisa-
tions and Medicare enrolment.
There were two main areas of investigation. The first was
the evaluation of differences in transfusion use and infec-
tion rates in hospitals and to calculate the intraclass (that
is, intrahospital) correlation coefficient. The second was
the assessment of the relationship between transfusion
and patient outcomes. The primary outcome was infec-
tion during hospitalisation. Secondary outcomes were
death (in-hospital and 30-days post discharge) and
readmission to a hospital (for any reason and for reason
of infection). For post-discharge outcomes, only those
individuals who survived to hospital discharge were
included in the analyses. Since infection was the primary
outcome, we excluded those patients who were initially
admitted for reason of infection (prior to the CABG pro-
cedure) and those with evidence of pre-existing infection
(for example, acquired immunodeficiency syndrome)
during the hospital stay when the CABG procedure
occurred. This constituted 0.4% of the sample (n = 115
patients).
Measures
Data regarding blood transfusions were extracted from
procedure codes (99.0×), as well as revenue codes for
blood products and services (38× for purchased blood
and 39× for donated blood). For purposes of these analy-
ses, the receipt of an allogeneic transfusion could have
included any of the following components at any time
during hospitalisation: red blood cells, whole blood,
platelets, plasma or cryoprecipitates. The use of autolo-
gous blood (where donor and recipient were the same
individual) was also obtained from two procedure codes
(99.00: perioperative autologous transfusion of whole
blood or blood components; 99.02: transfusion of previ-
ously collected autologous blood).
We determined infection by using ICD-9 codes that
explicitly stated infection (for example, 0xx.xx) or pro-
vided evidence of infection (purulent, suppurative, septic,
pyogenic or abscess). Data were also extracted regarding
age, gender, race, secondary diagnoses, type of admission
(elective, urgent, emergency), and length of stay. Less than
1% of values for race and type of admission were missing
and were imputed using best subset regression. We exam-
ined race at both the patient and hospital levels; specifi-
cally, for purposes of this investigation, hospitals were
classified as African-American if ≥ 50% of the patients
who received CABG surgery annually were African-Ameri-
can.
Surgeon volume was determined by summing the number
of Medicare CABG procedures per operating physician,
calculating the annual mean, and categorising into 2
equal groups based on the median number of cases per
year (60 CABG procedures/year). Hospital volume was
determined by summing the number of Medicare CABG
procedures and calculating the annual mean. We then cat-
egorised hospitals into 2 equal groups based on the
median number of cases per year (240 CABG procedures/Page 2 of 9
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correlation coefficients, the analyses were restricted to
those hospitals that performed at least 50 CABG proce-
dures (n = 40 hospitals).
Statistical analyses
Patient characteristics were evaluated first by receipt of all-
ogeneic blood transfusion. Bivariate associations were
assessed using Pearson χ2 tests for categorical data and the
Wilcoxon rank sum test for differences in median length
of hospital stay. Multilevel mixed-effects logistic regres-
sion was used to evaluate the associations between trans-
fusion and study outcomes (in-hospital infection, 30-day
readmission, 30-day mortality). A two-level hierarchical
model was used in which patients were nested within hos-
pitals. The hospital was modelled as a random intercept
with transfusion included as a fixed effect. The structure of
the covariance matrix for the random effect was specified
using the identity structure (uncorrelated random effects
with common variance). In postestimation, predicted
probabilities were calculated based on the linear predictor
of both fixed and random effects. The intraclass correla-
tion coefficient for the multilevel logistic model was cal-
culated as described by Snijders and Bosker [9].
In order to address the possible confounding effect of
comorbid conditions, propensity scores were calculated.
Specifically, we estimated the propensity for each person
to receive a transfusion in order to address the possibility
that recipients of blood transfusion had more underlying
illnesses than those not receiving transfusions. The prob-
ability of receiving an allogeneic blood transfusion was
based on the predicted values generated from logistic
regression using the following covariates: age, gender,
race, type of admission (elective, urgent, emergency), con-
gestive heart failure, diabetes mellitus, renal failure,
hypertension, chronic pulmonary disease, malignancy,
peripheral vascular disease, cerebrovascular disease, and
myocardial infarction (area under the receiver operating
characteristic curve = 0.7368). The scores were categorised
into deciles. Mean propensity scores were not different
among patients transfused and not transfused within each
block. In addition to adjustment for propensity decile, all
results controlled for surgeon volume and hospital vol-
ume. The α was set at 0.05, and all tests were two-tailed.
Stata/SE 10.0 software was used for all analyses (Stata,
College Station, TX, USA).
This study was approved by the Institutional Review
Board on Human Subjects at the University of Michigan at
Ann Arbor and by the Privacy Review Board at CMS.
Results
Patient characteristics
Of the 24,789 patients receiving CABG surgery in this
cohort, the majority were men (64%), white (92%), and
between the ages of 65 and 74 (54%). Table 1 lists the
characteristics of the patients. Nearly half of the CABG
procedures were performed during elective admissions,
and conditions such as diabetes mellitus, hypertension,
myocardial infarction, congestive heart failure and
chronic pulmonary disease were relatively frequent in this
cohort. The median length of hospital stay was 9 days in
patients who received a transfusion and 6 days in those
who did not (P < 0.001).
Transfusion
Transfusion during hospitalisation was common; alloge-
neic blood was given to 83.9% of patients and autologous
blood (only) was used for 1.2% of patients. Women were
more likely to receive a transfusion than men (93.6% vs
78.5%, respectively, for allogeneic blood). There was con-
siderable variation in the use of allogeneic blood across
hospitals (Figure 1), ranging from 49.7% to 100%
(median 82.2%) in men and from 72.5% to 100%
(median 95.7%) in women. Of patients who received a
transfusion, the number of units of blood was available
for only 1%; in this sample, there was a significant differ-
ence in the mean number of units of blood used across
hospitals (P < 0.0001).
Infection
Of the 24,789 patients in the study, 16.2% (n = 4,007)
had an infection during hospitalisation (18.0% in those
transfused with allogeneic blood; 9.7% in those trans-
fused with autologous blood only; and 6.6% in those not
transfused; P < 0.001). Receipt of allogeneic blood was
associated with infection across various sites (Table 2).
There was a statistically significant increase in infections
of the genitourinary system, respiratory tract, skin or sub-
cutaneous tissue and digestive tract in those given alloge-
neic blood, as well as an increase in septicaemia or sepsis,
other postoperative infections, and infection with Clostrid-
ium difficile.
There was also variation in infection rates across the hos-
pitals (Figure 2), with a greater frequency in women than
in men (21.1% vs 13.4%, respectively; P < 0.001). Hospi-
tal infection rates ranged from 3.9% to 34.2% in men and
from 7.7% to 43.0% in women.
Regression models
Odds ratios for the association between transfusion and
study outcomes are presented in Table 3. In general,
patients who received allogeneic transfusions (n =
20,789) exhibited poorer outcomes than patients who
received autologous transfusions only (n = 308). The odds
of infection during hospitalisation in patients who
received an allogeneic transfusion were twice that of
patients who were not transfused. For those receiving all-
ogeneic blood, the odds of death during hospitalisation
were elevated nearly fivefold with elective surgeries andPage 3 of 9
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odds of death in the 30 days after discharge were elevated
for elective surgeries nearly threefold and, for non-elective
surgeries, over fourfold with allogeneic blood. Readmis-
sion within 30 days post discharge was significantly
increased in those transfused with allogeneic blood,
regardless of type of surgery. Readmission for reason of
infection was not statistically significant, although it
approached significance for those who received allogeneic
blood with either urgent or emergency surgery.
The odds of infection, mortality and readmission were not
significantly elevated for patients who received only autol-
ogous blood compared to those not receiving any transfu-
sions, with one exception. The odds of in-hospital
infection were elevated with patients receiving autologous
transfusions with urgent or emergency surgery.
Using the predicted values from the final mixed-effects
model with propensity score adjustment, the rate of in-
hospital infection could be reduced to 13.1% (with 759
fewer cases in this population) if all hospital transfusion
Table 1: Characteristics of patients who underwent coronary artery bypass graft surgery
Allogeneic transfusion
Yes No Total
Patient characteristics n = 20,789 n = 4,000 n = 24,789 P value
Age (years): 65 to 69 5,069 (77%) 1,487 (23%) 6,556 (100%)
70 to 74 5,488 (82%) 1,238 (18%) 6,726 (100%)
75 to 79 5,761 (87%) 876 (13%) 6,637 (100%)
80 to 84 3,513 (91%) 350 (9%) 3,863 (100%)
≥ 85 958 (95%) 49 (5%) 1,007 (100%) < 0.001
Gender: Men 12,522 (78%) 3,438 (22%) 15,960 (100%)
Women 8,267 (94%) 562 (6%) 8,829 (100%) < 0.001
Race: White 19,035 (83%) 3,804 (17%) 22,839 (100%)
Black 1,250 (90%) 133 (10%) 1,383 (100%)
Other 504 (89%) 63 (11%) 567 (100%) < 0.001
Type of admission: Elective 9,183 (80%) 2,289 (20%) 11,472 (100%)
Urgent 6,035 (85%) 1,083 (15%) 7,118 (100%)
Emergency 5,571 (90%) 628 (10%) 6,199 (100%) < 0.001
Hospital CABG volume (annual mean): < 240 10,988 (87%) 1,595 (13%) 12,583 (100%)
≥ 240 9,801 (80%) 2,405 (20%) 12,206 (100%) < 0.001
Surgeon CABG volume (annual mean): < 60 10,796 (87%) 1,605 (13%) 12,401 (100%)
≥ 60 9,993 (81%) 2,395 (19%) 12,388 (100%) < 0.001
Coexisting conditions: Diabetes mellitus 5,747 (82%) 1,227 (18%) 6,974 (100%) < 0.001
Renal failure 2,006 (93%) 152 (7%) 2,158 (100%) < 0.001
Myocardial infarction 7,207 (86%) 1,157 (14%) 8,364 (100%) < 0.001
Congestive heart failure 6,593 (93%) 529 (7%) 7,122 (100%) < 0.001
Hypertension 11,063 (80%) 2,851 (20%) 13,914 (100%) < 0.001
Peripheral vascular disease 2,491 (84%) 474 (16%) 2,965 (100%) 0.813
Cerebrovascular disease 1,586 (86%) 265 (14%) 1,851 (100%) 0.027
Chronic pulmonary disease 5,014 (86%) 830 (14%) 5,844 (100%) < 0.001
Malignancy 463 (84%) 85 (16%) 548 (100%) 0.687
CABG = coronary artery bypass graft.
Variation across hospitals in use of allogeneic blood transfu-sion for men and women u derg ing coronary artery bypass graft surgeryFigure 1
Variation across hospitals in use of allogeneic blood 
transfusion for men and women undergoing coronary 
artery bypass graft surgery.Page 4 of 9
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50% at the hospital level, the expected rate of in-hospital
infection would be 11.8%, with 1,070 fewer patients
infected. For every 1% increase in the rate of transfusion,
there was a 0.13% increase in the probability of infection
at the hospital level.
Intraclass correlation coefficients
Intraclass correlation coefficients were calculated and are
listed in Table 4. Overall, the proportion of variation in
allogeneic transfusion attributable to hospital was
29.95% (95% CI 20.45% to 41.55%). This variation
remained similar across types of admission (elective,
urgent, emergency), patient age category, and gender.
However, the proportion of variation due to hospital was
considerably less for African-Americans than for whites
(6.47% and 29.97%, respectively). This finding was inves-
tigated further at both the patient level and hospital level
(Table 5). Patients who received their surgery at African-
American hospitals exhibited the greatest frequency of
adverse outcomes, regardless of their race.
Discussion
Variation by hospital
Variability in transfusion practices remains a concern.
Overall, 30% of the variability in transfusion practices
after CABG surgery was attributable to hospital site. This
variation was present regardless of the type of admission,
age group or gender of the patient. The overall intraclass
correlation coefficient, generated from actual patients in
this study, was slightly higher than an estimate calculated
from simulated data [10]. In a cross-sectional survey using
8 case simulations sent to physicians in 32 Canadian hos-
pitals in 2004 [10], the intrahospital correlation coeffi-
cient for red cell transfusion triggers in CABG surgery was
found to be 14.0% to 24.2%, depending upon the case
presentation and the time of administration (intraopera-
tive vs postoperative).
Our findings show that there was greater use of allogeneic
blood among African-Americans, as well as less variation
in transfusion practices across hospitals in such patients.
Cross-classifying by patient and hospital levels revealed
that the effects of race were particularly important at the
hospital level. African-American hospitals had elevated
rates of infection, mortality and readmission in patients of
all races. African-American patients had better outcomes
when they received surgery at non-African-American hos-
pitals. Kim and colleagues also reported a hospital effect
on mortality in African-Americans in a study of academic
medical centres in the US [11]. They found that receiving
CABG surgery at a higher volume hospital was of particu-
lar benefit to African-American patients.
There have been previous reports of hospital-wide differ-
ences in transfusion practices for patients receiving CABG
Table 2: Association between allogeneic blood transfusion and type of infection during hospitalisation for coronary artery bypass graft 
surgery
Outcome: Number (%) with infection during 
hospitalisation
Odds ratio for allogeneic transfusion* 
(95% CI)
P value
Genitourinary system infection 1,567 (6.3%) 1.27 (1.03, 1.55) 0.023
Respiratory tract infection 1,247 (5.0%) 2.45 (1.88, 3.21) < 0.001
Septicaemia or sepsis 506 (2.0%) 3.65 (2.22, 6.00) < 0.001
Infection of skin or subcutaneous tissue 392 (1.6%) 2.27 (1.48, 3.48) < 0.001
Postoperative infection (site undefined) 382 (1.5%) 2.02 (1.31, 3.11) 0.002
Infection with C. difficile 127 (0.5%) 3.16 (1.36, 7.35) 0.008
Circulatory system infection 130 (0.5%) 1.65 (0.92, 2.95) 0.093
Digestive tract infection 118 (0.5%) 2.11 (1.01, 4.44) 0.048
Note: some patients had more than one type of infection.
*Adjusted for propensity score, surgeon volume and hospital volume.
Variation across hospitals in infection for men and women undergoing c ronary artery bypass graft surgeryFigu e 2
Variation across hospitals in infection for men and 
women undergoing coronary artery bypass graft sur-
gery.Page 5 of 9
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[12], plasma use ranged from 0% to 97%; platelet use
ranged from 0% to 80%; and mean allogeneic red blood
cell use ranged from 0.4 to 6.3 units across hospitals. In a
study of 24 academic institutions using low-risk patients
only [13], 27% to 92% of patients were transfused with
packed red blood cells at the hospital level; 0% to 36% of
patients received platelets; 0% to 36% received fresh-fro-
zen plasma; and 0% to 17% of patients were given cryo-
precipitate. In an investigation of 14 Veterans
Administration Medical Centers [14], intraoperative
transfusion use in hospitals varied from 1.6% to 28.4%
for red blood cells, 0% to 9.7% for fresh-frozen plasma
and 4.8% to 18.4% for platelets. In a study of 5 university
teaching hospitals in the United States [15], transfusion of
all blood components ranged from 324 to 1,019 units
across hospitals. Such variation persisted in the late
1990s. In a study using 1996 to 2001 data from 32 US
hospitals [8], variation remained substantial ranging from
0% to 100% for various blood components.
Mandatory hospital-wide programs to improve transfu-
sion practices have resulted in some success in reducing
the use of transfusions [16], as have specific transfusion
Table 3: Odds ratios for the association between transfusion and outcomes for patients who underwent coronary artery bypass graft 
surgery
Outcomes: Number (%) with outcome Odds ratio for autologous 
transfusion (95% CI)*
P value Odds ratio for allogeneic 
transfusion (95% CI)*
P value
Elective surgery:
In-hospital infection 1,305 (11.4%) 1.02 (0.56, 1.86) 0.936 1.98 (1.59, 2.46) < 0.001
In-hospital mortality 325 (2.8%) 0.96 (0.12, 7.69) 0.968 4.67 (2.38, 9.18) < 0.001
30-day readmission to 
hospital
2,488 (22.3%) 0.70 (0.44, 1.12) 0.140 1.43 (1.25, 1.65) < 0.001
30-day readmission for 
infection
402 (3.6%) 0.94 (0.39, 2.24) 0.881 1.09 (0.82, 1.46) 0.555
30-day post-discharge 
mortality
155 (1.4%) 1.06 (0.13, 8.69) 0.957 2.88 (1.38, 5.98) 0.005
Urgent or emergency surgery:
In-hospital infection 2,702 (20.3%) 1.99 (1.12, 3.55) 0.019 1.82 (1.51, 2.20) < 0.001
In-hospital mortality 637 (4.8%) 1.24 (0.16, 9.68) 0.837 3.82 (2.18, 6.70) < 0.001
30-day readmission to 
hospital
3,610 (28.5%) 1.36 (0.79, 2.34) 0.266 1.68 (1.44, 1.96) < 0.001
30-day readmission for 
infection
543 (4.3%) 1.88 (0.72, 4.90) 0.199 1.39 (1.00, 1.93) 0.052
30-day post-discharge 
mortality
290 (2.3%) NE NE 4.65 (1.90, 11.39) 0.001
The comparison group consisted of patients who received no transfusions.
*Adjusted for propensity score, surgical volume and hospital volume.
NE = not estimable due to small numbers.
Table 4: Variation is use of allogeneic transfusion attributable to hospital for patients who underwent coronary artery bypass graft 
surgery
Group: Intraclass correlation coefficient 95% Confidence interval
Overall 29.95% 20.45% to 41.55%
Type of admission:
Elective 29.30% 19.67% to 41.22%
Urgent 25.68% 16.35% to 37.91%
Emergency 26.43% 16.14% to 40.14%
Age:
< 70 years 30.06% 19.85% to 42.71%
≥ 70 years 27.44% 18.26% to 39.04%
Gender:
Men 31.17% 21.15% to 43.33%
Women 24.77% 15.36% to 37.38%
Race:
White 29.97% 20.43% to 41.63%
African-American 6.47% 1.89% to 19.86%Page 6 of 9
(page number not for citation purposes)
BMC Medicine 2009, 7:37 http://www.biomedcentral.com/1741-7015/7/37guidelines in intensive care units [17] and the adoption of
transfusion coordinators [18]. Some hospitals have insti-
tuted bloodless surgery programs while others have uti-
lised restriction or management policies [19]. For
example, Earley and colleagues found that implementa-
tion of transfusion restriction practices significantly
reduced the incidence of ventilator-associated pneumonia
in trauma patients [20]. Evidence-based guidelines for
blood conservation techniques have been published with
specific recommendations for preoperative and intraoper-
ative measures to reduce blood use in the postoperative
period [21]. Such multimodal measures may warrant the
coordination of efforts across disciplines within the hos-
pital. In particular, research regarding interventions tar-
geted at hospitalists may be valuable.
Transfusion and adverse outcomes
Our finding of substantial variation is of particular con-
cern since the receipt of allogeneic blood yields risks as
well as benefits. The current study demonstrated increased
infection rates for different sites throughout the body sug-
gesting a systemic immunosuppressive effect in the recip-
ient. The increased risk of infection was apparent in the
bloodstream, respiratory tract, digestive tract, urinary
tract, skin, and non-specific sites. While the most com-
mon infections were of the genitourinary system and res-
piratory tract in our study, the strongest associations were
for septicaemia or sepsis and for infections with Clostrid-
ium difficile, both of which carry higher rates of mortality.
Allogeneic blood transfusion is not yet recognised as a risk
factor for C. difficile infection [22] but our data indicate
that this may be an issue for cardiac surgical patients.
Our findings are consistent with previous work in this
field. For example, a meta-analysis of 20 prospective stud-
ies (1986 to 2000) with 13,152 hospitalised patients,
reported a summary odds ratio for the relation between
blood transfusion and postoperative bacterial infection of
3.45 overall and 5.26 for trauma patients [23]. Mecha-
nisms underlying these adverse effects include the con-
tributory effects of leukocytes in allogeneic blood, which
resulted in widespread leukoreduction of blood compo-
nents [24,25]. Recent evidence points to possible storage
problems with blood. Changes in the red cell storage
lesion are time dependent and several studies have shown
increasing rates of infection, length of stay, and mortality,
as well as acute renal dysfunction in cardiac patients with
longer durations of storage [7,26]. Koch and colleagues
reported that cardiac patients who received red blood cells
that were stored for more than 14 days had significantly
higher rates of septicaemia or sepsis and mortality than
patients receiving red blood cells stored for a shorter
length of time [7].
Limitations
Our findings should be considered in the context of the
following limitations. First, by nature of the observational
study design, we cannot rule out unmeasured factors that
may account for these outcomes. In particular, we did not
measure left ventricular systolic function or left main cor-
onary artery disease, which may influence prognosis after
CABG surgery. Other important factors unavailable in this
database included procedural details (for example, intra-
aortic balloon pump, off-pump surgery), medication use
(for example, aprotinin), perioperative haemoglobin con-
centrations, and length of storage of the transfused blood.
Each of these factors could have been differentially dis-
tributed in patients at particular hospitals and therefore,
may have accounted for the hospital level variation in
practices or differences in patient outcomes.
Unfortunately, we could not adequately assess the effects
of specific blood components in this study. Although
most evidence points to the deleterious effects of red
blood cells on rates of nosocomial infection [1-5], there
are fewer investigations of the effects of platelets and
plasma, and such reports give conflicting results [27-31].
If the association with infection is specific for red blood
cells only, the pooling of patients with different blood
components in our study would have biased the reported
odds ratios towards the null.
In a previous investigation, the sensitivity and specificity
of using ICD-9 procedure codes for blood transfusion
have been found to be 83% and 100%, respectively [32].
In this study, revenue centre blood codes were also used
Table 5: Adverse outcomes by patient-level and hospital-level race
Percentage transfused Percentage with infection In-hospital mortality 30-Day readmission
African-American hospitals:
African-American patients 93.7% 34.5% 7.0% 51.2%
Other patients 90.0% 26.1% 5.7% 34.1%
Non-African-American hospitals:
African-American patients 89.5% 19.3% 4.9% 29.8%
Other patients 83.4% 15.7% 3.8% 24.0%Page 7 of 9
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using procedure codes alone.
Conclusion
In summary, we found that 30% of the variation in trans-
fusion practices was attributable to hospital. Allogeneic
but not autologous transfusion was associated with noso-
comial infection at multiple sites, readmission to the hos-
pital within 30 days after discharge, and mortality. The
safety of patients undergoing CABG will likely be
improved if hospitals carefully review current guidelines
on allogeneic blood transfusion, closely adhere to such
guidelines, and institute interventions to reduce inappro-
priate use of blood transfusions in recipients of CABG.
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